Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate.
Januszewski AS, Young HK, Ong KL, Li L, O'Connell RL, Lyons TJ, Kelly C, Zaharieva DP, Sullivan DR, Scott RS, Keech AC, Jenkins AJ; FIELD Study Investigators. Januszewski AS, et al. J Diabetes Investig. 2024 Nov;15(11):1663-1668. doi: 10.1111/jdi.14290. Epub 2024 Aug 22. J Diabetes Investig. 2024. PMID: 39171747 Free PMC article. Clinical Trial.
Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study.
Ong KL, Wu L, Januszewski AS, O'Connell RL, Xu A, Rye KA, Ma RCW, Li H, Jenkins AJ, Jia W, Keech AC; FIELD study investigators. Ong KL, et al. Among authors: januszewski as. Diabetes Res Clin Pract. 2020 Nov;169:108450. doi: 10.1016/j.diabres.2020.108450. Epub 2020 Sep 17. Diabetes Res Clin Pract. 2020. PMID: 32949655
The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study.
Ong KL, Wu L, Januszewski AS, O'Connell R, Xu A, Scott RS, Sullivan DR, Rye KA, Li H, Ma RC, Li L, Gebski V, Jenkins AJ, Jia W, Keech AC. Ong KL, et al. Among authors: januszewski as. Diab Vasc Dis Res. 2021 Jul-Aug;18(4):14791641211032547. doi: 10.1177/14791641211032547. Diab Vasc Dis Res. 2021. PMID: 34275349 Free PMC article. Clinical Trial.
Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes.
Jenkins AJ, O'Connell RL, Januszewski AS, Webster AC, M E Davis T, Jardine MJ, Scott RS, Taskinen MR, Keech AC; FIELD Trial Study Group. Jenkins AJ, et al. Among authors: januszewski as. Diabetes Res Clin Pract. 2024 Apr;210:111612. doi: 10.1016/j.diabres.2024.111612. Epub 2024 Mar 11. Diabetes Res Clin Pract. 2024. PMID: 38479447 Free article.
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL, Januszewski AS, O'Connell R, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Hung WT, Scott RS, Taskinen MR, Keech AC, Rye KA. Ong KL, et al. Among authors: januszewski as. Diabetologia. 2015 Mar;58(3):464-73. doi: 10.1007/s00125-014-3458-7. Epub 2014 Nov 26. Diabetologia. 2015. PMID: 25425220 Clinical Trial.
Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL, Januszewski AS, O'Connell R, Buizen L, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Rye KA, Keech AC; FIELD study investigators. Ong KL, et al. Among authors: januszewski as. Diabetologia. 2015 Sep;58(9):2035-44. doi: 10.1007/s00125-015-3652-2. Epub 2015 Jun 9. Diabetologia. 2015. PMID: 26055067 Clinical Trial.
Circulating microRNA Biomarkers of Diabetic Retinopathy.
Joglekar MV, Januszewski AS, Jenkins AJ, Hardikar AA. Joglekar MV, et al. Among authors: januszewski as. Diabetes. 2016 Jan;65(1):22-4. doi: 10.2337/dbi15-0028. Diabetes. 2016. PMID: 26696637 No abstract available.
Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Williams KH, Sullivan DR, Nicholson GC, George J, Jenkins AJ, Januszewski AS, Gebski VJ, Manning P, Tan YM, Donoghoe MW, Ehnholm C, Young S, O'Brien R, Buizen L, Twigg SM, Keech AC. Williams KH, et al. Among authors: januszewski as. Metabolism. 2016 May;65(5):783-793. doi: 10.1016/j.metabol.2015.12.008. Epub 2015 Dec 21. Metabolism. 2016. PMID: 27085785 Clinical Trial.
Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study.
Ong KL, O'Connell R, Januszewski AS, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Waldman B, Colman PG, Best JD, Simes JR, Rye KA, Keech AC; FIELD study investigators. Ong KL, et al. Among authors: januszewski as. Clin Chem. 2017 Jul;63(7):1261-1270. doi: 10.1373/clinchem.2016.270876. Epub 2017 Jun 12. Clin Chem. 2017. PMID: 28606915
96 results